Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
53
WST Quote, Financials, Valuation and Earnings
Last price:
$275.24
Seasonality move
:
4.44%
Day range:
$276.08 - $281.38
52-week range:
$187.43 - $348.90
Dividend yield:
0.31%
P/E ratio:
41.24x
P/S ratio:
6.72x
P/B ratio:
6.56x
Volume:
523.4K
Avg. volume:
670.5K
1-year change:
-16.27%
Market cap:
$20B
Revenue:
$2.9B
EPS (TTM):
$6.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$795.7M | $1.83 | 6.25% | 3.35% | $345.71 |
|
BDX
Becton, Dickinson & Co.
|
$5.2B | $2.81 | -0.31% | 169.42% | $204.83 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 15.75% | 105.65% | $125.86 |
|
ISRG
Intuitive Surgical, Inc.
|
$2.7B | $2.25 | 12.86% | 19.35% | $599.60 |
|
MASI
Masimo Corp.
|
$407.6M | $1.46 | -32.15% | 565.51% | $183.75 |
|
RMD
ResMed, Inc.
|
$1.4B | $2.71 | 8.96% | 16.17% | $291.80 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$278.44 | $345.71 | $20B | 41.24x | $0.22 | 0.31% | 6.72x |
|
BDX
Becton, Dickinson & Co.
|
$202.71 | $204.83 | $57.9B | 34.77x | $1.05 | 2.06% | 2.67x |
|
BSX
Boston Scientific Corp.
|
$98.65 | $125.86 | $146.2B | 52.77x | $0.00 | 0% | 7.61x |
|
ISRG
Intuitive Surgical, Inc.
|
$592.27 | $599.60 | $210B | 78.39x | $0.00 | 0% | 22.40x |
|
MASI
Masimo Corp.
|
$137.08 | $183.75 | $7.4B | 116.80x | $0.00 | 0% | 4.33x |
|
RMD
ResMed, Inc.
|
$248.21 | $291.80 | $36.2B | 25.40x | $0.60 | 0.91% | 6.95x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
9.03% | 1.594 | 1.61% | 2.02x |
|
BDX
Becton, Dickinson & Co.
|
44.09% | -0.449 | 37.48% | 0.47x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.384 | 8.31% | 0.81x |
|
ISRG
Intuitive Surgical, Inc.
|
-- | 1.051 | -- | 3.42x |
|
MASI
Masimo Corp.
|
41.99% | 0.887 | 7.4% | 1.68x |
|
RMD
ResMed, Inc.
|
12.15% | 0.549 | 2.12% | 1.89x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
WST
West Pharmaceutical Services, Inc.
|
$293.5M | $173.7M | 15.73% | 17.44% | 21.6% | $133.9M |
|
BDX
Becton, Dickinson & Co.
|
$2.8B | $881M | 3.72% | 6.6% | 14.96% | $1B |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
ISRG
Intuitive Surgical, Inc.
|
$1.7B | $759.7M | 16.35% | 16.38% | 30.33% | $735.6M |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
West Pharmaceutical Services, Inc. vs. Competitors
-
Which has Higher Returns WST or BDX?
Becton, Dickinson & Co. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 8.37%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Becton, Dickinson & Co.'s return on equity of 6.6%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B BDXBecton, Dickinson & Co.47.5% $1.72 $45.4B -
What do Analysts Say About WST or BDX?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 24.16%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $204.83 which suggests that it could grow by 1.05%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe West Pharmaceutical Services, Inc. is more attractive than Becton, Dickinson & Co..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 BDXBecton, Dickinson & Co.3 9 0 -
Is WST or BDX More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.167, which suggesting that the stock is 16.728% more volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.236, suggesting its less volatile than the S&P 500 by 76.383%.
-
Which is a Better Dividend Stock WST or BDX?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.31%. Becton, Dickinson & Co. offers a yield of 2.06% to investors and pays a quarterly dividend of $1.05 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BDX?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.9B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than Becton, Dickinson & Co.'s net income of $493M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 41.24x while Becton, Dickinson & Co.'s PE ratio is 34.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.72x versus 2.67x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.72x 41.24x $804.3M $140M BDXBecton, Dickinson & Co.2.67x 34.77x $5.9B $493M
-
Which has Higher Returns WST or BSX?
Boston Scientific Corp. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 14.91%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About WST or BSX?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 24.16%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 27.58%. Given that Boston Scientific Corp. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Boston Scientific Corp. is more attractive than West Pharmaceutical Services, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 BSXBoston Scientific Corp.25 2 0 -
Is WST or BSX More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.167, which suggesting that the stock is 16.728% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.
-
Which is a Better Dividend Stock WST or BSX?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.31%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or BSX?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than Boston Scientific Corp.'s net income of $755M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 41.24x while Boston Scientific Corp.'s PE ratio is 52.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.72x versus 7.61x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.72x 41.24x $804.3M $140M BSXBoston Scientific Corp.7.61x 52.77x $5.1B $755M
-
Which has Higher Returns WST or ISRG?
Intuitive Surgical, Inc. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 28.31%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B ISRGIntuitive Surgical, Inc.66.36% $1.95 $17B -
What do Analysts Say About WST or ISRG?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 24.16%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 1.24%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than Intuitive Surgical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 ISRGIntuitive Surgical, Inc.14 11 1 -
Is WST or ISRG More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.167, which suggesting that the stock is 16.728% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.
-
Which is a Better Dividend Stock WST or ISRG?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.31%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or ISRG?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 41.24x while Intuitive Surgical, Inc.'s PE ratio is 78.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.72x versus 22.40x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.72x 41.24x $804.3M $140M ISRGIntuitive Surgical, Inc.22.40x 78.39x $2.5B $709.2M
-
Which has Higher Returns WST or MASI?
Masimo Corp. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 14.46%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About WST or MASI?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 24.16%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 34.05%. Given that Masimo Corp. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Masimo Corp. is more attractive than West Pharmaceutical Services, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 MASIMasimo Corp.4 3 0 -
Is WST or MASI More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.167, which suggesting that the stock is 16.728% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.337%.
-
Which is a Better Dividend Stock WST or MASI?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.31%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or MASI?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are larger than Masimo Corp. quarterly revenues of $371.5M. West Pharmaceutical Services, Inc.'s net income of $140M is higher than Masimo Corp.'s net income of $53.7M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 41.24x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.72x versus 4.33x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.72x 41.24x $804.3M $140M MASIMasimo Corp.4.33x 116.80x $371.5M $53.7M
-
Which has Higher Returns WST or RMD?
ResMed, Inc. has a net margin of 17.41% compared to West Pharmaceutical Services, Inc.'s net margin of 26.1%. West Pharmaceutical Services, Inc.'s return on equity of 17.44% beat ResMed, Inc.'s return on equity of 25.6%.
Company Gross Margin Earnings Per Share Invested Capital WSTWest Pharmaceutical Services, Inc.36.49% $1.93 $3.4B RMDResMed, Inc.60.56% $2.37 $7B -
What do Analysts Say About WST or RMD?
West Pharmaceutical Services, Inc. has a consensus price target of $345.71, signalling upside risk potential of 24.16%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 17.56%. Given that West Pharmaceutical Services, Inc. has higher upside potential than ResMed, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings WSTWest Pharmaceutical Services, Inc.11 3 0 RMDResMed, Inc.8 7 1 -
Is WST or RMD More Risky?
West Pharmaceutical Services, Inc. has a beta of 1.167, which suggesting that the stock is 16.728% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.876, suggesting its less volatile than the S&P 500 by 12.416%.
-
Which is a Better Dividend Stock WST or RMD?
West Pharmaceutical Services, Inc. has a quarterly dividend of $0.22 per share corresponding to a yield of 0.31%. ResMed, Inc. offers a yield of 0.91% to investors and pays a quarterly dividend of $0.60 per share. West Pharmaceutical Services, Inc. pays 12.27% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios WST or RMD?
West Pharmaceutical Services, Inc. quarterly revenues are $804.3M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. West Pharmaceutical Services, Inc.'s net income of $140M is lower than ResMed, Inc.'s net income of $348.5M. Notably, West Pharmaceutical Services, Inc.'s price-to-earnings ratio is 41.24x while ResMed, Inc.'s PE ratio is 25.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services, Inc. is 6.72x versus 6.95x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income WSTWest Pharmaceutical Services, Inc.6.72x 41.24x $804.3M $140M RMDResMed, Inc.6.95x 25.40x $1.3B $348.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
